Breaking News

ImClone To Remain Independent

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImClone Systems plans to remain independent after several bidders failed to meet ImClone’s price in an auction that began in January, according to interim chief executive officer Joseph Fischer. Also, Carl C. Icahn has joined the company’s board and will be adding another board member of his choice. Mr. Icahn currently has a 10% stake in the company. The company is currently looking for a new chief executive officer. According to a company statement, ImClone no longer wants to b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters